Maria Grazia Narducci Anna Tosi Alessandra Frezzolini Enrico Scala Francesca Passarelli Laura Bonmassar Alessandro Monopoli Maria Pina Accetturi Maria Cantonetti Gian Carlo Antonini Cappellini Federica De Galitiis Antonio Rosato Mario Picozza Giandomenico Russo Stefania D'Atri
10.3389/fimmu.2020.579894
Front Immunol
2020 Sep 25;11:579894.
ki67 proliferation index pd-1 blockade therapy cutaneous t-cell lymphoma granzyme b immune sub-populations
CC BY
https://pubmed.ncbi.nlm.nih.gov/33072126/
Antineoplastic Agents, Immunological / therapeutic use CD4-Positive T-Lymphocytes / immunology CD8-Positive T-Lymphocytes / immunology Killer Cells, Natural / immunology Lymphoma, T-Cell / drug therapy Melanoma / drug therapy Neoplastic Cells, Circulating / pathology Nivolumab / therapeutic use Sezary Syndrome / drug therapy Skin Neoplasms / drug therapy
Antineoplastic Agents, Immunological / therapeutic use CD4-Positive T-Lymphocytes / immunology CD8-Positive T-Lymphocytes / immunology Killer Cells, Natural / immunology Lymphoma, T-Cell / drug therapy Melanoma / drug therapy Neoplastic Cells, Circulating / pathology Nivolumab / therapeutic use Sezary Syndrome / drug therapy Skin Neoplasms / drug therapy Case Reports Clinical Trial Research Support, Non-U.S. Gov't Aged Biomarkers, Tumor Female Humans Lymphoma, T-Cell / complications Male Melanoma / complications Programmed Cell Death 1 Receptor / antagonists & inhibitors Sezary Syndrome / complications Skin Neoplasms / complications Tumor Burden Antineoplastic Agents, Immunological Biomarkers, Tumor Programmed Cell Death 1 Receptor Nivolumab
PMC7544958
33072126
Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab
2020